BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s): BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp. > BioVaxys Is Now On FDA Official SRO List

<< Previous

Bullboard Posts

Next >>

Comment by ChaseAcklandon Jun 29, 2021 9:35am

72 Views

Post# 33465359

RE:RE:BioVaxys Is Now On FDA Official SRO List

I beleive it means that the FDA is actively reviewing something..the list is a way for FDA to make sure that there is no internal conflict of interest, i.e. FDA people holding shares of the company, relatives at company etc.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market